Abstract
The infant exposed to opioids in utero frequently presents a challenge to the neonatal care provider in the assessment and treatment of symptoms of Neonatal Abstinence Syndrome (NAS) after birth. This review is intended to provide the healthcare professional with a brief review of current evidence and practical guidelines for optimal evaluation and pharmacologic management of the opioid-exposed newborn.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Drug Therapy, Combination
-
Female
-
Humans
-
Infant, Newborn
-
Maternal Exposure
-
Maternal-Fetal Exchange
-
Methadone / administration & dosage
-
Methadone / therapeutic use*
-
Morphine / administration & dosage
-
Morphine / therapeutic use*
-
Narcotics / administration & dosage
-
Narcotics / therapeutic use*
-
Neonatal Abstinence Syndrome / diagnosis
-
Neonatal Abstinence Syndrome / drug therapy*
-
Opioid-Related Disorders / diagnosis
-
Opioid-Related Disorders / drug therapy*
-
Opioid-Related Disorders / rehabilitation
-
Practice Guidelines as Topic
-
Pregnancy
-
Prenatal Exposure Delayed Effects / drug therapy*
Substances
-
Narcotics
-
Morphine
-
Methadone